Press Release

Jun, 27 2023

The Global Lung Cancer Surgery Market: A Comprehensive Overview

Lung cancer is the leading cause of cancer death in both men and women in the United States. In 2022, it is estimated that 235,770 people will be diagnosed with lung cancer, and 158,040 people will die from the disease. The most common cause of lung cancer is smoking. Smoking causes about 80% of all lung cancer deaths. Other risk factors for lung cancer include exposure to secondhand smoke, radon, asbestos, and certain chemicals. The symptoms of lung cancer can vary depending on the stage of the disease. Early-stage lung cancer often does not cause any symptoms.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-lung-cancer-surgery-market

Data Bridge Market Research analyses that the Lung Cancer Surgery Market will grow at a CAGR of 5.50% from 2022 to 2029 and is expected to reach USD 5,092.07 million by 2029 from USD 3,317.98 million in 2021. Growing lung cancer awareness programs by non-profit, private, and public organizations are driving market expansion. These efforts seek to reduce stigma and discrimination, as well as to prevent disease and promote research. The preceding remark indicates that population awareness of lung cancer has increased due to numerous awareness programs run by various organizations; people are aware that lung cancer can be cured if detected early. As a result, increasing public awareness is driving the worldwide lung cancer surgery market.

Lung Cancer Surgery Market

Growing prevalence of air pollution is expected to drive the market's growth rate

The global lung cancer surgery market is predicted to grow during the forecast period due to rising lung cancer prevalence caused by factors such as rising air pollution levels and an increasing number of cigarette smokers. According to the American Association for Thoracic Surgery, lung cancer was the top cause of cancer deaths in the United States in 2012. The rising global incidence of lung cancer is a significant driver of this market's expansion.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014- 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Surgical Instruments, Monitoring & Visualizing System, Endosurgical Equipment, Robotic-Assisted Thoracic Surgery Systems And Others), Surgical Procedure (Thoracotomy And Minimally Invasive Surgery), Patient Type (Male And Female), End User (Hospitals, Ambulatory Surgical Centres, Academic & Research Laboratories, Speciality Cancer Care Centres And Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AngioDynamics (U.S.), Ackermann (U.S.), Scanlan International (U.S.), KLS Martin Group (Germany) Wexler Surgical (U.S.), Lepu Medical Technology(Beijing)Co.,Ltd. (China), Intuitive Surgical (U.S.), FusionKraft (India), Surgical Holdings (U.S.), GerMedUSA (U.K.), Medtronic (Ireland), Accuray Incorporated (U.S.), Teleflex Incorporated (U.S.), KARL STORZ SE & Co. KG (Germany), TROKAMED GmbH (Germany), Richard Wolf GmbH (Germany), Sontec Instruments, Inc. (U.S.), asap endoscopic products GmbH (Germany), Ambu A/S (Denmark), Johnson & Johnson Private Limited (U.S.), FUJIFILM Holdings Corporation (Japan), Olympus Corporation (Japan)

Data Points Covered in the Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework

Segment Analysis:

The lung cancer surgery market is segmented on the basis of product type, surgical procedure, patient type, end user and distribution channel.

  • On the basis of product type, the global lung cancer surgery market is segmented into surgical instruments, monitoring & visualizing systems, endosurgical equipment, robotic-assisted thoracic surgery systems, and others.

The surgical instruments segment of product type segment is anticipated to dominate the lung cancer surgery market

The surgical instruments segment is expected to dominate the market and is expected to reach USD 2132.44 million by 2030, due to a rise in the prevalence of lifestyle disorders that ultimately require surgery. Moreover, significant unmet surgical demands and increasing healthcare expenses will boost the growth of this segment in the market.

  • On the basis of surgical procedure, the global lung cancer surgery market is segmented into thoracotomy and minimally invasive surgeries. Thoracotomy segment is expected to dominate the market and is expected to reach USD 3349.78 million by 2030, due to augmented prevalence of lung cancer disorder.
  • On the basis of patient type, the global lung cancer surgery market is segmented into male and female. Male segment is expected to dominate the market and is expected to reach USD 3051.82 million by 2030 due to an increase in the smoking habit of males. The usage of tobacco has been reported to be the main reason for lung cancer disorders in males.
  • On the basis of end-user, the global lung cancer surgery market is segmented into hospitals, ambulatory surgical centers, academic and research laboratories, specialty cancer care centers, and others.

The hospitals segment of end-user segment is anticipated to dominate the lung cancer surgery market

The hospitals segment is expected to dominate the market and is expected to reach USD 2476.95 million by 2030 due to the availability of advanced surgical products in the hospitals. Moreover, increasing number of patients admitted in hospitals and rising disposable income of people will also dominate the hospital segment in the market.

  • On the basis of distribution channel, the global lung cancer surgery market is segmented into direct tender, retail sales, online sales, and others. Direct tender segment is expected to dominate the market and is expected to reach USD 2759.95 million by 2030 due to the increase in contractual agreements between distributors and manufacturers for surgical devices and equity in the tendering process.

Major Players

Data Bridge Market Research recognizes the following companies as the major market players: AngioDynamics (U.S.), Ackermann (U.S.), Scanlan International (U.S.), KLS Martin Group (Germany) Wexler Surgical (U.S.), Lepu Medical Technology(Beijing)Co.,Ltd. (China), Intuitive Surgical (U.S.), FusionKraft (India), Surgical Holdings (U.S.), GerMedUSA (U.K.), Medtronic (Ireland), Accuray Incorporated (U.S.), Teleflex Incorporated (U.S.), KARL STORZ SE & Co. KG (Germany), TROKAMED GmbH (Germany), Richard Wolf GmbH (Germany), Sontec Instruments, Inc. (U.S.), asap endoscopic products GmbH (Germany), Ambu A/S (Denmark), Johnson & Johnson Private Limited (U.S.), FUJIFILM Holdings Corporation (Japan), Olympus Corporation (Japan).

Lung Cancer Surgery Market

Market Development

  • In 2022, Ethicon, a subsidiary of Johnson & Johnson Services, Inc., announced the launch of the ECHELON 3000 Stapler. This next-generation surgical stapler is designed to provide surgeons with greater access and control during procedures. The ECHELON 3000 features a 27% larger articulation span and a 39% larger jaw aperture than its predecessor, the ECHELON 2000. This allows surgeons to access and transect challenging tissue more easily, even in tight spaces. The ECHELON 3000 also features a new software system that provides the surgeon real-time haptic and audible feedback. This feedback helps surgeons make critical adjustments during procedures and ensure the stapler is properly positioned.
  • In 2020, Olympus Corporation announced the launch of the EVIS X1 endoscopy system. This new system is designed to improve the outcomes of endoscopic procedures. The EVIS X1 features several new technologies, including high-definition camera that provides surgeons with a clear and detailed view of the inside of the body, A narrow-band imaging technology that enhances the contrast of tissue structures, making it easier to identify tumors and other abnormalities, and a miniature probe that can be inserted into small spaces, such as the bile ducts and pancreatic ducts.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in the lung cancer surgery market during the forecast period 2022-2029

North America is the dominating region in the global lung cancer surgery market. The high prevalence of lung cancer and the increasing number of early-stage lung cancer diagnoses are the major factors driving the growth of North America's lung cancer surgery market.

Asia-Pacific is estimated to be the fastest growing region in the lung cancer surgery market in the forecast period 2022-2029

Asia-Pacific is expected to be the fastest-growing global lung cancer surgery region. The high prevalence of lung cancer and the increasing number of hospitals and clinics equipped with advanced surgical facilities are the major factors driving the growth of the lung cancer surgery market in Asia-Pacific.

For more detailed information about the lung cancer surgery market report, click here – https://www.databridgemarketresearch.com/reports/global-lung-cancer-surgery-market


Client Testimonials